



COMPARATIVE BIOSCIENCES, INC.

A TRANSLATIONAL APPROACH TO PRECLINICAL RESEARCH

Investigational
New Drug
Application
Approved



Congratulations to all of our clients and colleagues who have launched successful INDs this past year!

CBI, leaders in Stem Cell Pharmacology and GLP Toxicology, congratulates our Friends and Colleagues on their FDA IND successes in 2014:

VIACYTE INC.

**Stem Cell and Device Diabetes Therapy
Transforming the Lives of Patients with Diabetes**

XERIS PHARMACEUTICALS, INC.

**Novel delivery system for Glucagon
Partners in the Diabetes Community**

CELDARA MEDICAL, LLC-Novel Cancer Treatment

UCSD-UC-961 (cirmtuximab) Cancer Treatment

CBI is the industry leader in conducting difficult and complicated IND enabling and research studies including stem cells and stem-cell device combination studies, delivery systems, diabetes and cancer therapies.

CONGRATULATIONS FRIENDS AND COLLEAGUES



Contact us for more information and to discuss your complex IND needs.

[CLICK HERE:
Pharmacology](#)

[CLICK HERE:
Stem Cell Research](#)

[CLICK HERE:
Antibacterial Research & Consulting](#)